Published in J Drugs Dermatol on May 01, 2012
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22
Psoriasis and its comorbidities. J Drugs Dermatol (2012) 1.02
Evaluating Clinical Use of a Ceramide-dominant, Physiologic Lipid-based Topical Emulsion for Atopic Dermatitis. J Clin Aesthet Dermatol (2011) 0.85
Advances in the Understanding of the Pathogenesis of Inflammatory Acne. J Drugs Dermatol (2016) 0.83
What is new in fungal pharmacotherapeutics? J Drugs Dermatol (2014) 0.80
Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. J Drugs Dermatol (2013) 0.80
Use of a topical emulsion for wound healing. J Support Oncol (2008) 0.79
Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids. J Clin Aesthet Dermatol (2011) 0.78
A double-blind, placebo-controlled pilot study to estimate the efficacy and tolerability of a nonsteroidal cream for the treatment of cradle cap (seborrheic dermatitis). J Drugs Dermatol (2013) 0.78
Evolving concepts in the pathogenesis of acne vulgaris. J Drugs Dermatol (2014) 0.78
The importance of photoprotection and moisturization in treating acne vulgaris. J Drugs Dermatol (2014) 0.78
Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. J Drugs Dermatol (2016) 0.77
Re-evaluating treatment targets in acne vulgaris: adapting to a new understanding of pathophysiology. J Drugs Dermatol (2014) 0.76
Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol (2014) 0.76
Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach. J Drugs Dermatol (2014) 0.76
A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay. J Drugs Dermatol (2014) 0.76
The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician? J Drugs Dermatol (2013) 0.76
Treatment of facial photodamage using a novel retinol formulation. J Drugs Dermatol (2013) 0.76
Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Dapsone 5% Gel Combination Treatment. J Drugs Dermatol (2016) 0.75
Bensal HP for Second Intention Healing Following Mohs Micrographic Surgery or Shave Skin Biopsy: An Open-label Pilot Study. J Drugs Dermatol (2016) 0.75
Understanding the Role of Photolyases: Photoprotection and Beyond. J Drugs Dermatol (2017) 0.75
The only topical retinoid without a generic alternative: tazarotene. J Drugs Dermatol (2013) 0.75
The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris. J Drugs Dermatol (2017) 0.75
Do we really need topical antibiotics in our new treatment paradigm of acne vulgaris? A novel question to consider based on an updated model of pathogenesis. J Drugs Dermatol (2013) 0.75
Use of naftifine hydrochloride 2% cream and 39% urea cream in the treatment of tinea pedis complicated by hyperkeratosis. J Drugs Dermatol (2014) 0.75
Why do we need another moisturizer for our acne patients? J Drugs Dermatol (2014) 0.75
Evidence-Based Skincare: The Importance of Offering Moisturization, Relief, and Protection in Common Skin Disorders. J Drugs Dermatol (2016) 0.75
Effect of skin barrier emulsion cream vs a conventional moisturizer on transepidermal water loss and corneometry in atopic dermatitis: a pilot study. J Drugs Dermatol (2014) 0.75
Challenges and advances in rosacea management. J Drugs Dermatol (2014) 0.75
Randomized, controlled, evaluator-blinded studies conducted to compare the efficacy and tolerability of 3 over-the-counter acne regimens in subjects with mild or moderate acne. J Drugs Dermatol (2013) 0.75
Advancements in Topical Antifungal Vehicles. J Drugs Dermatol (2016) 0.75
Understanding generics. J Drugs Dermatol (2014) 0.75
Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid. J Drugs Dermatol (2014) 0.75
Evaluating tretinoin formulations in the treatment of acne. J Drugs Dermatol (2014) 0.75
Onychomycosis: Strategies to Minimize Recurrence. J Drugs Dermatol (2016) 0.75
Practical aspects of topical corticosteroid selection. J Drugs Dermatol (2012) 0.75
Randomized, Double-Blind, Split-Face Study to Compare the Irritation Potential of Two Topical Acne Formulations Over a 21-Day Treatment Period. J Drugs Dermatol (2016) 0.75
Over-the-counter product role in the daily management of atopic dermatitis: achieving success with advanced technology. J Drugs Dermatol (2013) 0.75
Optimizing topical antifungal therapy for superficial cutaneous fungal infections: focus on topical naftifine for cutaneous dermatophytosis. J Drugs Dermatol (2013) 0.75
Not all topical corticosteroids are created equal! Optimizing therapeutic outcomes through better understanding of vehicle formulations, compound selection,and methods of application. J Drugs Dermatol (2012) 0.75
Introduction to Advances in Tinea Pedis Management. J Drugs Dermatol (2016) 0.75
Fixed Combination of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75% Aqueous Gel: Long-Term Use in Adult Females With Moderate Acne Vulgaris. J Drugs Dermatol (2017) 0.75
Psoriasis Is a Chronic Disease: Long Term Efficacy and Safety of New Biologics Is Important. J Drugs Dermatol (2017) 0.75
Onychomycosis: Does Cure Equate to Treatment Success? J Drugs Dermatol (2016) 0.75
The microsponge delivery system reduces facial oiliness and shine during acne therapy. J Drugs Dermatol (2013) 0.75
Spotlight on the Use of Nitric Oxide in Dermatology: What Is It? What Does It Do? Can It Become an Important Addition to the Therapeutic Armamentarium for Skin Disease? J Drugs Dermatol (2017) 0.75
A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion. J Drugs Dermatol (2017) 0.75
The Power of Combination Topical Therapy for Psoriasis. J Drugs Dermatol (2015) 0.75
Put your best foot forward: advances in the management of tinea pedis. J Drugs Dermatol (2013) 0.75
Understanding and Addressing the Acne Vulgaris Paradigm Shift. J Drugs Dermatol (2016) 0.75